Abstract
Studies in EGFR+ non-small cell lung cancer (NSCLC) patients with leptomeningeal metastasis (LM) comparing survival rates and gene mutation detection with matched cerebrospinal fluid (CSF) and plasma are relatively scarce. We evaluated gene mutations, treatment strategies, and clinical outcomes in EGFR+ NSCLC patients with LM. We retrospectively reviewed gene mutation status in the CSF and plasma of 32 EGFR+ NSCLC patients with LM for prognostic significance. The rate of LM disease control was significantly higher in patients that switched EGFR-tyrosine kinase inhibitor (TKI) treatments, initiated EGFR-TKIs, or received high-dose EGFR-TKI treatment than those who continued their current EGFR-TKI treatment, received chemotherapy, or were not administered antitumor treatment (24/24, 100.0% vs. 1/8, 12.5%; P = 0.000). Overall survival was 27.0 months (95% confidence interval [CI] 19.0-37.5), median survival after LM was 7.0 months (95% CI 5.0-11.0), and median survival before LM was 17.0 months (95% CI 12-25.5). Median survival after LM was significantly shorter in patients with "worse" status (n = 7) than in those with "improved/stable" status (n = 25; 4.2 [95% CI 2.2-6.1] vs. 33.7 [95% CI 25.5-41.8] months, HR 10.114, 95% CI 0.2...Continue Reading
References
Dec 2, 2008·Journal of Neuro-oncology·Fusako WakiTomohide Tamura
Feb 11, 2010·Journal of Neuro-oncology·Jennifer L ClarkeAndrew B Lassman
May 5, 2010·Neurology·J L ClarkeL M Deangelis
Nov 18, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Patrick G MorrisAntonio M Omuro
Jan 19, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Su Jin LeeMyung-Ju Ahn
Feb 5, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·J L Kuiper, E F Smit
Feb 21, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ho-Shin GwakSeung Hoon Lee
Jun 5, 2014·Cancer Discovery·Darren A E CrossWilliam Pao
Sep 24, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Petra HoffknechtUNKNOWN Afatinib Compassionate Use Consortium (ACUC)
May 6, 2015·Nature Medicine·Kenneth S ThressGeoffrey R Oxnard
May 13, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew J NiederstJeffrey A Engelman
Jun 29, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Justine L KuiperEgbert F Smit
Aug 27, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Akito HataYasushi Yatabe
Jul 21, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter BallardDarren Cross
Dec 14, 2016·The New England Journal of Medicine·Tony S MokUNKNOWN AURA3 Investigators
May 13, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·June-Koo LeeYoung Seok Ju
Jun 20, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Chee-Seng TanRoss A Soo
Jul 19, 2018·The Lancet. Respiratory Medicine·Zhijie WangJie Wang
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Le RhunUNKNOWN EANO Executive Board and ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Citations
May 13, 2020·Journal of breast cancer·Marcela CarausuLuc Cabel
Aug 28, 2021·Cancers·Daniel Di CapuaStephen Finn
Oct 12, 2021·International Journal of Clinical Pharmacy·Shaohong LuoXiongwei Xu